Two possible cases of erenumab‐induced xerostomia
- 22 December 2021
- journal article
- case report
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (6) , 824-825
Abstract
What is known and objective Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug. Case summary We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented with dry mouth after the first and second dose. What is new and conclusion Xerostomia is not described as an adverse reaction in the drug's technical datasheet. A search was made in PubMed including ‘erenumab’, ‘fremanezumab’, ‘galcanezumab’, ‘xerostomia’, and no results were found. It is necessary to identify this potential adverse reaction in order to estimate its prevalence and possible impact on patients’ quality of life.Keywords
This publication has 5 references indexed in Scilit:
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VIDrugs in R&D, 2016
- Manejo actual de la xerostomíaRevista chilena de obstetricia y ginecología, 2016
- Comparación de dos métodos de evaluación de causalidad de sospechas de reacciones adversas a medicamentos (RAM): 2003-2009Revista médica de Chile, 2015
- XerostomiaThe Journal of the American Dental Association, 2003
- The enhancement of carbachol‐induced salivary secretion by VIP and CGRP in rat parotid gland is mimicked by forskolinActa Physiologica Scandinavica, 1989